Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Pelvic Neoplasms 1Leiomyoma 1Desmoid Tumors 1Colorectal Neoplasms 1Chylous Ascites 1Abdominal Neoplasms 1

Interventions

Bevacizumab 120Fluorouracil 90Cetuximab 84Leucovorin 82Oxaliplatin 80pembrolizumab 70Irinotecan 66Nivolumab 46Capecitabine 43Specimen Handling 40regorafenib 30Folfox protocol 29trifluridine tipiracil drug combination 28Magnetic Resonance Spectroscopy 27Biopsy 27Panitumumab 26HMPL-013 26Standard of Care 25IFL protocol 21Gemcitabine 20Blood Specimen Collection 19tislelizumab 18atezolizumab 18Trifluridine 18Cisplatin 18balstilimab 16Colonoscopy 16Carboplatin 16encorafenib 15Paclitaxel 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colorectal Neoplasms × Embolization, Therapeutic × 1 year × Clear all
NCT07612007 2026-06-01

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

Mayo Clinic

Phase 2 Not yet recruiting
80 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡